The Shift in Global Drug Development
Episode publishedPodcast: The a16z ShowThe a16z Show
Transcript preview
Preview only
America is 4% of the world's population. It's about 13% of all the drug buying, but it's also more than half of the sales in terms of dollar amounts. So it's huge. And this is a big advantage because like, you know, innovation does respond to the money and it has to. Are more likely to have false positives and false negatives in our trials because they are smaller than theirs. Theirs are less likely to have both. The Type one and Type two error rates are both down for China because they run bigger, better trials. China says, well, no, profitable. We're actually going to make you money. If you
What happens when The United States is no longer the leader in biomedical innovation? For decades, The US dominated drug development, producing a large share of the world's new therapies and setting the pace for clinical research. But over the last few years, that started to change. China has rapidly expanded its clinical trial system, accelerated approvals, and is now leading in both volume and novel drug development. This shift isn't about scale. It's about systems, regulatory design, trial structure, funding models, and incentives all shape how quickly new treatments reach patients and wher
Welcome to MTS Cremieux Recue. How do you pronounce it in the French?
Creme u rue que.
Creme u rue que.
That was pretty good. We're gonna add you That like a you had a slight Canadian accent there.
To the tweet wall. Uh-oh.
Straight over the tweet wall.
Let me make this bigger so can look at it.
Keep exploring with a free account.
A free account preserves the short preview. Upgrade to Pro for the full transcript and episode chat.
This episode could not be prepared.
Try again to prepare the episode for reading and questions.